CGP 48506
Alternative Names: BA 41899Latest Information Update: 04 Dec 2003
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Developer Nonindustrial source; Novartis
- Class Cardiotonics; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 04 Dec 2003 No development reported - Preclinical for Heart failure in Germany (unspecified route)
- 04 Dec 2003 No development reported - Preclinical for Heart failure in Switzerland (unspecified route)
- 04 Oct 2000 Two preclinical studies have been added to the Heart Failure pharmacodynamics section ,